Research map: Global multicenter validation of noninvasive fibrosis assessment pathways in MetALD and ALD

Back to the article

Papers in this map

  1. Design and validation of a histological scoring system for nonalcoholic fatty liver disease† · David Erwin Kleiner · 2005 · 10909 citations · Cited by this paper
  2. Fibrosis detection in steatotic liver disease in women of reproductive age: a retrospective analysis · Denisse Rubio-Cruz · 2026 · Cites this paper
  3. CRISPLD2 protects against liver inflammation and fibrosis via GRP78 to repress HMGB1/TLR4 axis–mediated STING palmitoylation · 2026 · Related
  4. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection†‡ · Richard K. Sterling · 2006 · 5001 citations · Cited by this paper
  5. Neoadjuvant therapy in primary liver cancer: From the missing piece to a new paradigm · 2026 · Related
  6. A multisociety Delphi consensus statement on new fatty liver disease nomenclature · Mary Eugenia Rinella · 2023 · 3201 citations · Cited by this paper
  7. Prospective validation of a real-time natural language processing pipeline for the extraction of elastography results from electronic health record data · 2026 · Related
  8. Baveno VII – Renewing consensus in portal hypertension · Roberto de Franchis · 2021 · 2898 citations · Cited by this paper
  9. Reply: High mortality at safety-net hospitals for patients with cirrhosis · 2026 · Related
  10. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease · Mary Eugenia Rinella · 2023 · 2555 citations · Cited by this paper
  11. Multi-threshold analysis of the ELF Test versus histology for prognostication of disease progression and regression in MASH · 2026 · Related
  12. EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) · Frank Tacke · 2024 · 2049 citations · Cited by this paper
  13. Manufacturing and electrostatic surface optimization of CAR-T cells improve therapeutic efficacy in liver malignancies · 2026 · Related
  14. Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease · Arun Jayant Sanyal · 2021 · 1134 citations · Cited by this paper
  15. IL15-mediated crosstalk between LSECs and CD8⁺ tissue-resident memory T cells drives alcohol-associated hepatitis · 2026 · Related
  16. Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis · Stuart McPherson · 2016 · 945 citations · Cited by this paper
  17. Efficacy, safety, and pharmacokinetics of rifaximin in pediatric patients with hepatic encephalopathy in Japan: An open-label study · 2026 · Related
  18. Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease · Fasiha Kanwal · 2021 · 610 citations · Cited by this paper
  19. Contemporary global epidemiology of cirrhosis · 2026 · Related
  20. Use of Liver Imaging and Biopsy in Clinical Practice · Elliot B. Tapper · 2017 · 444 citations · Cited by this paper
  21. The role of ammonia in chronic liver disease · 2026 · Related
  22. Prognostic accuracy of FIB‐4, NAFLD fibrosis score and APRI for NAFLD‐related events: A systematic review · Jenny Lee · 2020 · 383 citations · Cited by this paper
  23. Steatotic liver disease · Mads Egerod Israelsen · 2024 · 350 citations · Cited by this paper
  24. Fibrosis and alcohol-related liver disease · Carolin Lackner · 2019 · 340 citations · Cited by this paper
  25. Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage · Mohammad Shadab Siddiqui · 2019 · 274 citations · Cited by this paper
  26. Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, Elastography, and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease · Maja Sofie Thiele · 2018 · 273 citations · Cited by this paper
  27. AASLD Practice Guideline on imaging-based noninvasive liver disease assessment of hepatic fibrosis and steatosis · Richard K. Sterling · 2024 · 206 citations · Cited by this paper
  28. Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease · David Martí Aguado · 2024 · 202 citations · Cited by this paper
  29. The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease · Luis Antonio Díaz · 2023 · 201 citations · Cited by this paper
  30. Metabolic dysfunction and alcohol-related liver disease (MetALD): Position statement by an expert panel on alcohol-related liver disease · Juan Pablo Arab · 2024 · 170 citations · Cited by this paper
  31. Update of liver fibrosis and steatosis with transient elastography (Fibroscan) · Grace Lai‐Hung Wong · 2013 · 108 citations · Cited by this paper
  32. Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021 · Lene Ryom · 2022 · 108 citations · Cited by this paper
  33. Non‐invasive tests for liver fibrosis in NAFLD: Creating pathways between primary healthcare and liver clinics · Laurent Castéra · 2020 · 91 citations · Cited by this paper
  34. Effect of alcohol consumption on liver stiffness measured by transient elastography · Edouard Bardou‐Jacquet · 2013 · 87 citations · Cited by this paper
  35. Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver disease · Terry Cheuk‐Fung Yip · 2025 · 58 citations · Cited by this paper
  36. Updated recommendations for the management of metabolic dysfunction–associated steatotic liver disease (MASLD) by the Latin American working group · Luis Antonio Díaz · 2025 · 58 citations · Cited by this paper
  37. Transient elastography alone and in combination with FibroTest® for the diagnosis of hepatic fibrosis in alcoholic liver disease · Cosmin Sebastian Voican · 2017 · 51 citations · Cited by this paper
  38. Noninvasive tests for liver fibrosis in 2024: are there different scales for different diseases? · Jimmy Che‐To Lai · 2023 · 49 citations · Cited by this paper
  39. Adverse Liver Outcomes, Cardiovascular Events, and Mortality in Steatotic Liver Disease · Pedro Ochoa‐Allemant · 2025 · 44 citations · Cited by this paper

Source: OpenAlex (CC0)